⚠️Educational purposes only. Not medical advice. Consult a licensed provider before use. Many peptides are research-grade compounds not FDA-approved. Verify legal status in your jurisdiction.
← Back to library
PT-141
Bremelanotide (PT-141)
Strong RCTFDA Approved
An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder — works centrally on the brain, not the vascular system.
Mechanism of action
Melanocortin receptor agonism, central nervous system arousal pathways, dopamine activation
Primary benefits
- ✓Increased sexual desire (men & women)
- ✓Improved arousal
- ✓FDA-approved for HSDD in women
- ✓Central action — no cardiovascular effect
Dosing
Beginner
0.5-1 mg as needed
Intermediate
1-1.75 mg as needed
Advanced
1.75-2 mg as needed
Frequency: As needed — 45-60 min before activity
Timing: 45-60 minutes before activity
Route: Subcutaneous injection, Intranasal
Cycling protocol
Duration
As needed
Pattern
No more than once per 72 hours
Break after
N/A — as needed use
Important warnings
- ⚠️FDA-approved for HSDD in premenopausal women (Vyleesi)
- ⚠️Nausea common — take anti-nausea medication prophylactically
- ⚠️Avoid in cardiovascular disease
- ⚠️Prescription required